ArticleJournal of clinical microbiology2024
Evaluation of the STANDARD M10 MDR-TB and MTB/NTM assays for the detection of
Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of rapid nucleic acid amplification tests for tuberculosis on patient outcomes.The Cochrane database of systematic reviews · 2025Pooled it
- Evaluation of clinical usefulness of a commercial multiplex PCR for diagnosing mycobacterial infections: a multicenter study.Microbiology spectrum · 2026Article
- Accuracy of nanopore-based targeted next-generation sequencing assay for detection ofJournal of clinical microbiology · 2026Article
- Molecular Techniques for MTBC and NTM Differentiation: Diagnostic Accuracy of STANDARD™ M10 MTB/NTM and Potential Applications.Diagnostics (Basel, Switzerland) · 2026Article
- Rapid Molecular Diagnostics of Tuberculosis: What Do We Have, What Do We Need?Pulmonary medicine · 2026Review
- A High Sensitive Detection of Droplet Digital PCR for the Diagnosis of Pulmonary Tuberculosis.Infection and drug resistance · 2026Article
- Genomic characterization of multidrug-resistant tuberculosis in Shanghai, China: antibiotic resistance, virulence and transmission.JAC-antimicrobial resistance · 2025Article
- Evaluation of the Standard M10 MTB/NTM Molecular Test for the Rapid Identification of Tuberculous and Nontuberculous Mycobacteria in Liquid Cultures.Pathogens (Basel, Switzerland) · 2025Article
- Diagnostic value of GeneXpert MTB/RIF in bronchoalveolar lavage fluid for pulmonary non-tuberculosis mycobacterial in acid-fast stain smear-positive and GeneXpert MTB/RIF-negative cases.Journal of thoracic disease · 2025Article
- Rapid identification of majorFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rapid detection is crucial for tuberculosis (TB) control. GeneXpert (Cepheid) is a widely used PCR system, known for its simplicity, random access, and point-of-care compatibility. SD BIOSENSOR recently introduced a similar system, STANDARD M10, including a IMPORTANCE: The molecular diagnostic STANDARD M10 system is highly analogous to the widely established GeneXpert system, which significantly increases the relevance of this evaluation study in the field of rapid detection of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.